Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Intelsius Introduces Reusable Courier Transit Case

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
BioCarrier™ - Designed for local courier routes and multiple site sample collections.

Intelsius has introduced the first of its kind range of solutions, BioCarrier™, specifically designed for local courier routes and multiple site sample collections.

“Intelsius is proudly introducing the BioCarrier line to the life science leaders and industry professionals at the largest and most well attended clinical trial conference of the year,” said David Walsh, CEO, Intelsius. “This is a regulatory compliant solution rather than couriers carrying samples or medicines from clinic to clinic or pharmacy to pharmacy in picnic coolers.”

BioCarrier cases are designed to provide regular route, multiple site sample collection and “home visit” temperature-sensitive injectable drug protection.

The rugged polymer outer with the expanded polypropylene (EPP) insulated liner maintains payload integrity at 2-8 degrees Celsius for 12 hours plus or when using dry ice up to 18 hours.

All three sizes are regulatory compliant with pre-printed UN3373 labels for the shipment of Category B biological samples.

“The rigid, durable, regulatory compliant marked outer cases feature a clasp closure allowing the lid to be secured and the cases to be stacked and locked together, making them an Intelsius exclusive,” said Alex Roskoss, Intelsius European head of technical services.

“These cases were ergonomically designed specifically for couriers to enable safe, comfortable, compliant transportation around the corner or across town,” Roskoss added. Its discreet design keeps the contents confidential.

“Keeping people safe while samples or medicines are being transported around town is the primary reason for creating the BioCarrier line of products,” said Walsh.

Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos